Loading organizations...
MQB Partners is a global healthtech investment management firm. It originates, invests in, and manages healthtech ventures for clients, leveraging specialized expertise across gene therapy, molecular medicine, neuroscience, and digital health. This approach cultivates high-potential opportunities within the evolving health technology landscape.
The firm was founded by experienced entrepreneurs and investors: Marko Bogoievski, Caroline Quay, Dr Scott McPhee, and Dr Ken Chin. These partners bring extensive leadership and investment backgrounds in healthcare and technology. Their insight into the need for specialized management in the complex global healthtech market prompted the firm's creation.
MQB Partners serves clients seeking expert oversight of healthtech investment portfolios. Its vision focuses on fostering groundbreaking health technology companies reshaping healthcare delivery and outcomes. Through meticulous investment selection and nurturing, the firm aims to drive significant advancements and impact across the global health ecosystem.
MQB Partners has 1 tracked investment across 1 company. The latest tracked deal is $47.0M Series B in Cerevance in April 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2024 | Cerevance | $47.0M Series B | Bioluminescence Ventures, Campbell Murray, Double Point Ventures | ARCH Venture Partners, David Schenkein, Issi Rozen, GV, LUX Capital, Morgenthaler Ventures, SV Health Investors, Bill Gates, Gates Frontier, Liferock Ventures, Lightstone Ventures |